Determination of piroxicam in pharmaceutical formulations and urine samples using europium-sensitized luminescence

Salma M.Z. Al-Kindy*, Fakhr Eldin O. Suliman, Aisha A. Al-Wishahi, Haidar A.J. Al-Lawati, Muhammed Aoudia

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


A simple, selective and sensitive luminescence method for the assay of piroxicam (PX) in aqueous solution is developed. The method is based on the luminescence sensitization of europium (Eu3+) by formation of ternary complex with PX in the presence of TOPO and Tween-80 as surfactant. The signal for Eu-PX-TOPO is monitored at λex=359 nm and λem=615 nm. Optimum conditions for the formation of the complex in sequential injection analysis (SIA) were 0.01 M Tris buffer, pH 7.5, TOPO 5.0×10-5 M, Tween-80 0.15% and 1.5 mM of Eu3+, which allows the determination of 100-1000 ppb of PX with limit of detection (LOD) of 29 ppb. The relative standard deviations of the method range between 0.5% and 3.9% indicating excellent reproducibility of the method. The proposed method was successfully applied for the assay of PX in pharmaceutical formulations and in urine samples. Average recoveries of 100.8±1.7% was obtained in tablet, whereas a recovery of 97.5±2.0% was obtained for the total PX (PX+hydoxy-PX) in urine sample.

Original languageEnglish
Pages (from-to)291-296
Number of pages6
JournalJournal of Luminescence
Issue number2
Publication statusPublished - Dec 2007


  • Europium
  • Piroxicam
  • Sensitized luminescence
  • Sequential injection
  • Urine

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • General Chemistry
  • Atomic and Molecular Physics, and Optics
  • Condensed Matter Physics


Dive into the research topics of 'Determination of piroxicam in pharmaceutical formulations and urine samples using europium-sensitized luminescence'. Together they form a unique fingerprint.

Cite this